![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » MEDICURE INC. ACQUIRES U.S. RIGHTS TO AGGRASTAT FROM MGI PHARMA, INC.
MEDICURE INC. ACQUIRES U.S. RIGHTS TO AGGRASTAT FROM MGI PHARMA, INC.
Medicure Inc., a cardiovascular focused biopharmaceutical company, announced that the company has acquired the exclusive U.S. rights to AGGRASTAT Injection (tirofiban hydrochloride) from MGI PHARMA, INC. AGGRASTAT, a glycoprotein (GP) IIb/IIIa inhibitor, is used for the treatment of acute coronary syndrome (ACS) including unstable angina and non-Q-wave myocardial infarction.
BioSpace
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct